FDA Places Full Clinical Hold on CTI BioPharma’s Myelofibrosis Candidate

Citing a “detrimental effect on survival,” the FDA has placed a full clinical hold on CTI BioPharma’s myelofibrosis candidate pacritinib.
Source: Clinical Trials Advisor